Polyelectrolyte multilayers using the polycations chitosan and N,N,N-trimethyl chitosan and the polyanions hyaluronan, chondroitin sulfate, and heparin are studied. Chitosan and hyaluronan behave as a weak polycation and weak polyanion, respectively, whereas N,N,N-trimethyl chitosan, chondroitin sulfate, and heparin behave as strong polyelectrolytes. Hydrophilicity is determined by water contact angle measurements and by comparing wet and dry film thickness measurements. Wet thickness is obtained using Fourier transform surface plasmon resonance, whereas dry thickness is obtained through ellipsometry. For the very thin PEMs studied here, the surface hydrophilicity and swelling in water are highly correlated. The multilayer chemistry is assessed by FT-IR and X-ray photoelectron spectroscopy (XPS). FT-IR and XPS provide information about the composition, degree of ionization, and by inference, the ion pairing. We find that hydrophilicity and swelling are reduced when one polyelectrolyte is strong and the other is weak, whereas ion pairing is increased. By this combination of techniques, we are able to compose a unified description of how the PEM swelling is dictated by the ion pairing in thin polysaccharide-based PEMs.

It is generally accepted that both surface chemistry and biochemical cues affect mesenchymal stem cell (MSC) proliferation and differentiation. Several growth factors that have strong influences on MSC behavior bind to glycosaminoglycans in interactions that affect their stability and their biochemical activity. The goal of this work was to develop polysaccharide-based polyelectrolyte multilayers (PEMs) to bind and stabilize growth factors for delivery to MSCs. Using the naturally derived polysaccharides chitosan and heparin, PEMs were constructed on gold-coated glass chips, tissue-culture polystyrene (TCPS), and titanium. PEM construction and basic fibroblast growth factor (FGF-2) adsorption to PEMs were evaluated by Fourier transform surface plasmon resonance, X-ray photoelectron spectroscopy, and polarization modulation infrared reflection absorption spectroscopy. The functional response of bone marrow-derived ovine MSCs to FGF-2 on PEM-coated TCPS and titanium was evaluated in vitro, in the presence and absence of adsorbed fibronectin. The effect of FGF-2 dose and presentation on MSC attachment and proliferation was evaluated using low-serum media, over four days. On PEM-coated TCPS, we found that FGF-2 adsorbed to heparin-terminated PEMs with adsorbed fibronectin induces greater cell density and a higher proliferation rate of MSCs than any of the other conditions tested, including delivery of the FGF-2 in solution, at an optimally mitogenic dose. Cell densities on day four were 1.8 times higher when FGF-2 was delivered by adsorption to the PEM than when FGF-2 was delivered in solution. This system represents a promising candidate for the development of surface coatings that can stabilize and potentiate the activity of growth factors for therapeutic applications. Interestingly, the same effects were not observed when FGF-2 was delivered by adsorption to PEMs on titanium. When the polysaccharide-based PEMs were formed on titanium, the proliferative response of ovine MSCs to adsorbed FGF-2 was not as strong as the response to FGF-2 delivered in solution.

Synaptotagmin 2 is a synaptic vesicle protein that functions as a calcium sensor for neurotransmission but has not been previously associated with human disease. Via whole-exome sequencing, we identified heterozygous missense mutations in the C2B calcium-binding domain of the gene encoding Synaptotagmin 2 in two multigenerational families presenting with peripheral motor neuron syndromes. An essential calcium-binding aspartate residue, Asp307Ala, was disrupted by a c.920A>C change in one family that presented with an autosomal-dominant presynaptic neuromuscular junction disorder resembling Lambert-Eaton myasthenic syndrome. A c.923C>T variant affecting an adjacent residue (p.Pro308Leu) produced a presynaptic neuromuscular junction defect and a dominant hereditary motor neuropathy in a second family. Characterization of the mutation homologous to the human c.920A>C variant in Drosophila Synaptotagmin revealed a dominant disruption of synaptic vesicle exocytosis using this transgenic model. These findings indicate that Synaptotagmin 2 regulates neurotransmitter release at human peripheral motor nerve terminals. In addition, mutations in the Synaptotagmin 2 C2B domain represent an important cause of presynaptic congenital myasthenic syndromes and link them with hereditary motor axonopathies.

No abstract

Objectives: To describe the clinical and electrophysiologic features of synaptotagmin II (SYT2) mutations, a novel neuromuscular syndrome characterized by foot deformities and fatigable ocular and lower limb weakness, and the response to modulators of acetylcholine release. Congenital myasthenic syndromes (CMS) are a heterogeneous group of disorders caused by abnormal signal transmission between motor axons and skeletal muscle. Methods:1 Mutations in an increasing number of presynaptic proteins, components of the synaptic basal lamina, proteins involved in endplate development and maintenance, and more recently in protein glycosylation 2 have been reported, causing novel and complex phenotypes. Since most CMS are treatable, diagnosing them is of utmost importance.Signal transmission at the neuromuscular junction is mediated via the release of acetylcholine from synaptic vesicles.3 This process is rendered calcium sensitive by members of the synaptotagmin protein family, which also have a role in vesicle priming and in reducing spontaneous transmitter release.4,5 Synaptotagmin II (SYT2) is the major isoform expressed at the neuromuscular junction, and Syt2 knockout mice show markedly reduced calcium-evoked transmitter release.6 Synaptotagmins interact with SNAP-25, 5 and mutations in SNAP25B have been described in patients with myasthenia and additional CNS phenotypes. Herein, we describe the clinical and electrophysiologic characteristics of 2 multigenerational families displaying a novel human motor syndrome caused by dominant SYT2 mutations: c.920T.G